Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 2 Diabetes

Next Previous
Trial Profile

A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Tonghua Dongbao Pharmaceutical

Most Recent Events

  • 08 Jun 2026 According to a Adocia media release, the company will host a virtual Key Opinion Leader (KOL) event on Tuesday June 16, 2026 at 10:00 AM EST / 4:00 PM CEST. to review the results of the Phase 3 trial conducted in China
  • 08 Jun 2026 According to a Adocia media release, full results of the Phase 3 clinical study were presented at the American Diabetes Association (ADA) 86th Scientific Session (June 5-8, 2026 in New Orleans), completing the positive topline results of this clinical trial announced in July 2025.
  • 22 Dec 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top